Investors / Media

Dicot is a pharmaceutical company focused on developing new drugs for the treatment of sexual dysfunction in men, such as erection problems and premature ejaculation. The company's drug candidate, Libiguin®, is in the preclinical development phase. Dicot is listed on the Spotlight Stock Market and has approximately 1 600 shareholders.

Reasons for investing in Dicot:

  • The market for sexual dysfunctions is valued at over SEK 60 billion per year and is rapidly growing because there is an increased population of older people and improved general public health
  • Many men (30%) diagnosed with erectile dysfunction do not respond to treatment with PDE5 inhibitors
  • Dicot's drug candidate Libiguin® has a long duration of action, ~10-14 days, unlike PDE5 inhibitors, which are "on-demand products" and must be taken shortly before planned sexual activity
  • There is an unmet need for a good drug treatment on the market today
  • Dicot's drug candidate, Libiguin®, originates from nature and has a longstanding medicinal use for treating erection problems in folk medicine
  • High probability with phase 2 data to generate very good financial returns through deals with pharma companies in several regions across the globe
  • Strong and dedicated leadership team and Board of Directors to bring the company into a successful exit for the shareholders

Follow us

Contact us

Dicot AB
Dag Hammarskjölds Väg 30
SE-752 37 Uppsala SWEDEN
+46 (0) 70-663 60 09

The information is processed according to our privacy policy.